Hypotonic-hyporesponsive Episodes After Diphtheria, Tetanus and Acellular Pertussis Vaccination.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
23
8
2021
medline:
19
1
2022
entrez:
22
8
2021
Statut:
ppublish
Résumé
Hypotonic-hyporesponsive episode (HHE) after whole cell pertussis vaccination is a known adverse event. Less is known about the risk of HHE after administration of acellular pertussis vaccines. Using parental interviews, this study actively surveyed for HHE among infants after doses 1 and 2 of acellular pertussis vaccine. We interviewed the parents of 52,531 infants. HHE was reported at a rate of 22.8 per 100,000 doses (95% CI: 11.8-39.9) of acellular pertussis vaccine, approximately 45 episodes per 100,000 children. These rates are lower than HHE rates reported after whole cell pertussis vaccines and within the range of HHE rates reported in other studies of acellular pertussis vaccines.
Sections du résumé
BACKGROUND
Hypotonic-hyporesponsive episode (HHE) after whole cell pertussis vaccination is a known adverse event. Less is known about the risk of HHE after administration of acellular pertussis vaccines.
METHODS
Using parental interviews, this study actively surveyed for HHE among infants after doses 1 and 2 of acellular pertussis vaccine.
RESULTS
We interviewed the parents of 52,531 infants. HHE was reported at a rate of 22.8 per 100,000 doses (95% CI: 11.8-39.9) of acellular pertussis vaccine, approximately 45 episodes per 100,000 children.
CONCLUSIONS
These rates are lower than HHE rates reported after whole cell pertussis vaccines and within the range of HHE rates reported in other studies of acellular pertussis vaccines.
Identifiants
pubmed: 34420008
doi: 10.1097/INF.0000000000003308
pii: 00006454-900000000-95703
pmc: PMC8575166
doi:
Substances chimiques
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1122-1126Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
S.B. is currently a consultant for Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline and the World Health Organization and received study support funding from Sanofi Pasteur as an investigator on the trial. N.P.K. has received research support from Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer and Protein Sciences (now Sanofi Pasteur). The other authors have no conflicts of interest to disclose.
Références
Lancet. 1997 Nov 29;350(9091):1569-77
pubmed: 9393335
Vaccine. 2004 Jan 26;22(5-6):563-8
pubmed: 14741145
Pediatrics. 1998 Nov;102(5):E52
pubmed: 9794982
MMWR Morb Mortal Wkly Rep. 2002 Jan 18;51(2):31-3
pubmed: 11820528
N Engl J Med. 1996 Feb 8;334(6):349-55
pubmed: 8538705
MMWR Recomm Rep. 2002 Feb 8;51(RR-2):1-35
pubmed: 11848294
Cochrane Database Syst Rev. 2014 Sep 17;(9):CD001478
pubmed: 25228233
J Pediatr. 1996 Nov;129(5):695-701
pubmed: 8917236
Pediatrics. 2000 Oct;106(4):E52
pubmed: 11015547
Vaccine. 2007 Aug 1;25(31):5875-81
pubmed: 17537554
Dev Biol Stand. 1997;89:101-3
pubmed: 9272338
Biologicals. 1999 Jun;27(2):79-86
pubmed: 10600188